1 Table of Contents 1 Table of Contents 2 1.1 List of Tables 4 1.2 List of Figures 6 2 Introduction 7 2.1 Dry Powder Inhaler Devices Overview 7 3 Products under Development 8 3.1 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development 8 3.2 Dry Powder Inhaler Devices - Pipeline Products by Territory 9 3.3 Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path 10 3.4 Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date 11 3.5 Dry Powder Inhaler Devices - Ongoing Clinical Trials 12 4 Dry Powder Inhaler Devices - Pipeline Products under Development by Companies 13 4.1 Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development 13 4.2 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development 15 5 Dry Powder Inhaler Devices Companies and Product Overview 16 5.1 Acorda Therapeutics, Inc. Company Overview 16 5.1.1 Acorda Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 16 5.2 Adamis Pharmaceuticals Corporation Company Overview 19 5.2.1 Adamis Pharmaceuticals Corporation Pipeline Products & Ongoing Clinical Trials Overview 19 5.3 Advent Pharmaceuticals Pty Ltd Company Overview 22 5.3.1 Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 22 5.4 Aespira Ltd. Company Overview 23 5.4.1 Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview 23 5.5 AKELA Pharma Inc. (Inactive) Company Overview 24 5.5.1 AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 24 5.6 Bayer HealthCare AG Company Overview 26 5.6.1 Bayer HealthCare AG Pipeline Products & Ongoing Clinical Trials Overview 26 5.7 Bespak Europe Ltd. Company Overview 28 5.7.1 Bespak Europe Ltd. Pipeline Products & Ongoing Clinical Trials Overview 28 5.8 GlaxoSmithKline Plc Company Overview 29 5.8.1 GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview 29 5.9 Hovione FarmaCiencia SA Company Overview 31 5.9.1 Hovione FarmaCiencia SA Pipeline Products & Ongoing Clinical Trials Overview 31 5.10 MannKind Corporation Company Overview 33 5.10.1 MannKind Corporation Pipeline Products & Ongoing Clinical Trials Overview 33 5.11 Nanotherapeutics, Inc. Company Overview 35 5.11.1 Nanotherapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 35 5.12 Nektar Therapeutics Company Overview 38 5.12.1 Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview 38 5.13 Novartis AG Company Overview 40 5.13.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 40 5.14 OPKO Health, Inc. Company Overview 44 5.14.1 OPKO Health, Inc. Pipeline Products & Ongoing Clinical Trials Overview 44 5.15 Pharmaxis Limited Company Overview 46 5.15.1 Pharmaxis Limited Pipeline Products & Ongoing Clinical Trials Overview 46 5.16 Respira Therapeutics, Inc. Company Overview 48 5.16.1 Respira Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 48 5.17 Sandoz International GmbH Company Overview 49 5.17.1 Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview 49 5.18 Sheffield Hallam University Company Overview 52 5.18.1 Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview 52 5.19 Shin Nippon Biomedical Laboratories, Ltd. Company Overview 53 5.19.1 Shin Nippon Biomedical Laboratories, Ltd. Pipeline Products & Ongoing Clinical Trials Overview 53 5.20 Teva Pharmaceutical Industries Ltd. Company Overview 55 5.20.1 Teva Pharmaceutical Industries Ltd. Pipeline Products & Ongoing Clinical Trials Overview 55 5.21 University of Kansas Company Overview 57 5.21.1 University of Kansas Pipeline Products & Ongoing Clinical Trials Overview 57 5.22 University of Texas Medical Branch at Galveston Company Overview 58 5.22.1 University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview 58 6 Dry Powder Inhaler Devices- Recent Developments 60 6.1 Mar 30, 2016: 80 Years of Innovation and Success in Healthcare: Chiesi Reports Significant International Growth in 2015 60 6.2 Mar 07, 2016: New Health Outcomes Data Reinforce Role of Device Selection and Peak Inspiratory Flow Rate in Treatment of COPD Patients 61 6.3 Oct 20, 2015: GSK announces positive new data comparing Incruse Ellipta to tiotropium and glycopyrronium in patients with COPD 62 6.4 Jun 16, 2015: Consort Medical announces final results 63 7 Appendix 69 7.1 Methodology 69 7.2 About GlobalData 71 7.3 Contact Us 72 7.4 Disclaimer 72

1.1 List of Tables Table 1: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development 8 Table 2: Dry Powder Inhaler Devices - Pipeline Products by Territory 9 Table 3: Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path 10 Table 4: Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date 11 Table 5: Dry Powder Inhaler Devices - Ongoing Clinical Trials 12 Table 6: Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development 13 Table 7: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development 15 Table 8: Acorda Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 16 Table 9: CVT-301 Drug Delivery Device - Product Status 17 Table 10: CVT-301 Drug Delivery Device - Product Description 17 Table 11: CVT-427 Drug Delivery Device - Product Status 18 Table 12: CVT-427 Drug Delivery Device - Product Description 18 Table 13: Adamis Pharmaceuticals Corporation Pipeline Products & Ongoing Clinical Trials Overview 19 Table 14: 3M Taper Dry Powder Inhaler - Product Status 20 Table 15: 3M Taper Dry Powder Inhaler - Product Description 20 Table 16: APC-5000 - Dry Powder Inhaler - Product Status 21 Table 17: APC-5000 - Dry Powder Inhaler - Product Description 21 Table 18: Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 22 Table 19: g60 Dry Powder Inhaler - Product Status 22 Table 20: g60 Dry Powder Inhaler - Product Description 22 Table 21: Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview 23 Table 22: resQhaler - Product Status 23 Table 23: resQhaler - Product Description 23 Table 24: AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 24 Table 25: Fentanyl TAIFUN Inhaler - Product Status 25 Table 26: Fentanyl TAIFUN Inhaler - Product Description 25 Table 27: Bayer HealthCare AG Pipeline Products & Ongoing Clinical Trials Overview 26 Table 28: Ciprofloxacin Dry Powder Inhaler - Product Status 27 Table 29: Ciprofloxacin Dry Powder Inhaler - Product Description 27 Table 30: Bespak Europe Ltd. Pipeline Products & Ongoing Clinical Trials Overview 28 Table 31: DEV610 - Product Status 28 Table 32: DEV610 - Product Description 28 Table 33: GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview 29 Table 34: Gemini Multi-Dose Combination Inhaler - Product Status 30 Table 35: Gemini Multi-Dose Combination Inhaler - Product Description 30 Table 36: Hovione FarmaCiencia SA Pipeline Products & Ongoing Clinical Trials Overview 31 Table 37: XCaps - Product Status 32 Table 38: XCaps - Product Description 32 Table 39: MannKind Corporation Pipeline Products & Ongoing Clinical Trials Overview 33 Table 40: Dreamboat - Product Status 34 Table 41: Dreamboat - Product Description 34 Table 42: Nanotherapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 35 Table 43: GelVac Intranasal Powder Vaccine Delivery System - Product Status 36 Table 44: GelVac Intranasal Powder Vaccine Delivery System - Product Description 36 Table 45: NanoGENT - Product Status 37 Table 46: NanoGENT - Product Description 37 Table 47: Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview 38 Table 48: Nektar Dry Powder Inhaler - Amikacin - Product Status 39 Table 49: Nektar Dry Powder Inhaler - Amikacin - Product Description 39 Table 50: Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 40 Table 51: Ultibro Breezhaler - Product Status 41 Table 52: Ultibro Breezhaler - Product Description 41 Table 53: Novartis AG - Ongoing Clinical Trials Overview 42 Table 54: Ultibro Breezhaler - The Effectiveness of Single Dose Ultibro Breezhaler (Indacaterol/Glycopyrronium) by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in Improving FEV1 and Dyspnea During Stable State of COPD 43 Table 55: OPKO Health, Inc. Pipeline Products & Ongoing Clinical Trials Overview 44 Table 56: Inspiromatic - Product Status 45 Table 57: Inspiromatic - Product Description 45 Table 58: Pharmaxis Limited Pipeline Products & Ongoing Clinical Trials Overview 46 Table 59: Orbital Dry Powder Inhaler - Product Status 47 Table 60: Orbital Dry Powder Inhaler - Product Description 47 Table 61: Respira Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 48 Table 62: Dry Powder Inhaler - Product Status 48 Table 63: Dry Powder Inhaler - Product Description 48 Table 64: Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview 49 Table 65: Solis Multi-Dose Dry Powder Inhaler - Product Status 50 Table 66: Solis Multi-Dose Dry Powder Inhaler - Product Description 50 Table 67: Unit-Dose Dry Powder Inhaler - Product Status 51 Table 68: Unit-Dose Dry Powder Inhaler - Product Description 51 Table 69: Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview 52 Table 70: Dry Powder Inhaler - Product Status 52 Table 71: Dry Powder Inhaler - Product Description 52 Table 72: Shin Nippon Biomedical Laboratories, Ltd. Pipeline Products & Ongoing Clinical Trials Overview 53 Table 73: µco System - Product Status 54 Table 74: µco System - Product Description 54 Table 75: Teva Pharmaceutical Industries Ltd. Pipeline Products & Ongoing Clinical Trials Overview 55 Table 76: Spiromax EU / mDPI US - Product Status 56 Table 77: Spiromax EU / mDPI US - Product Description 56 Table 78: University of Kansas Pipeline Products & Ongoing Clinical Trials Overview 57 Table 79: Dry Powder Inhaler - Product Status 57 Table 80: Dry Powder Inhaler - Product Description 57 Table 81: University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview 58 Table 82: Dry Powder Drug Delivery System - Product Status 59 Table 83: Dry Powder Drug Delivery System - Product Description 59 Table 84: Glossary 70 1.2 List of Figures Figure 1: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development 8 Figure 2: Dry Powder Inhaler Devices - Pipeline Products by Territory 9 Figure 3: Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path 10 Figure 4: Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date 11 Figure 5: Dry Powder Inhaler Devices - Ongoing Clinical Trials 12

Acorda Therapeutics, Inc. Adamis Pharmaceuticals Corporation Advent Pharmaceuticals Pty Ltd Aespira Ltd. AKELA Pharma Inc. Bayer HealthCare AG Bespak Europe Ltd. GlaxoSmithKline Plc Hovione FarmaCiencia SA MannKind Corporation Nanotherapeutics, Inc. Nektar Therapeutics Novartis AG OPKO Health, Inc. Pharmaxis Limited Respira Therapeutics, Inc. Sandoz International GmbH Sheffield Hallam University Shin Nippon Biomedical Laboratories, Ltd. Teva Pharmaceutical Industries Ltd. University of Kansas University of Texas Medical Branch at Galveston